Several members of Congress questioned the FDA's review of Dendreon Corp.'s (Nasdaq: DNDN) prostate cancer treatment Provenge saying that two panel advisors had financial ties to Dendreon rivals. An investigation into the panel's rejection Provenge was requested sending shares of the biotechnology firm soaring $1.34 to close at $6.98.
Congress Requests Probe Of FDA Rejection Of Dendreon's Provenge
December 13, 2007 at 16:43 PM EST